Literature DB >> 29589063

Patterns of direct oral anticoagulant drug prescription in France in 2010-2013: a study in the Midi-Pyrénées area.

Hugo Diaz1, Haleh Bagheri2,3, Aurore Palmaro4,5,6,7, Vanessa Rousseau4,5,6, Robert Bourrel8, Jean-Louis Montastruc4, Jordan Birebent1.   

Abstract

AIM: The aim of our study was to study the pattern of prescription of direct-acting oral anticoagulants (DOACs) according to the French recommendations.
METHODS: We performed a cross-sectional study using anonymous data of patients covered by the French National Health Insurance information system (SNIIRAM) from 1 January 2010 to 31 December 2013 in the area of Midi-Pyrénées (southwest of France).
RESULTS: Of the 355,608 patients identified, 325,216 (91.5%) were included, of whom 22,142 received at least one DOAC. About 39.1% (8,652 patients) had DOAC in an orthopedic indication, 46.5% (10,303 patients) in a cardiac indication, and 16.1% (3568 patients) in an indeterminate indication. Overall, guidelines were largely followed as for renal function monitoring, prescribing in orthopedic indications, in cardiac indications in patients aged 80 years and older, and in the case of concomitant use of verapamil. However, inappropriate prescriptions were observed for cardiac indications, and for dosage adjustments in orthopedic indications, with respect to both the age of patients (75 years and older) and those taking verapamil or amiodarone concomitantly. Guidelines were more followed in women and patients aged 80 or more.
CONCLUSIONS: Among patients receiving DOACs, 58% were exposed to a prescription falling outside the guidelines. This study on DOAC prescription patterns revealed insufficiencies in the compliance with the French guidelines in certain indications.

Entities:  

Keywords:  Direct oral anticoagulants; French guidelines; Pattern of prescription

Mesh:

Substances:

Year:  2018        PMID: 29589063     DOI: 10.1007/s00228-018-2449-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?

Authors:  Aurore Palmaro; Quentin Boucherie; Julie Dupouy; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-03-07       Impact factor: 2.890

2.  Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.

Authors:  Nihar R Desai; Alexis A Krumme; Sebastian Schneeweiss; William H Shrank; Gregory Brill; Edmund J Pezalla; Claire M Spettell; Troyen A Brennan; Olga S Matlin; Jerry Avorn; Niteesh K Choudhry
Journal:  Am J Med       Date:  2014-05-21       Impact factor: 4.965

Review 3.  French health insurance databases: What interest for medical research?

Authors:  G Moulis; M Lapeyre-Mestre; A Palmaro; G Pugnet; J-L Montastruc; L Sailler
Journal:  Rev Med Interne       Date:  2014-12-26       Impact factor: 0.728

4.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

Review 5.  Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies.

Authors:  Aurore Palmaro; Guillaume Moulis; Fabien Despas; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Fundam Clin Pharmacol       Date:  2016-07-13       Impact factor: 2.748

6.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

7.  Immeasurable time bias in observational studies of drug effects on mortality.

Authors:  Samy Suissa
Journal:  Am J Epidemiol       Date:  2008-05-30       Impact factor: 4.897

8.  Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.

Authors:  Géric Maura; Pierre-Olivier Blotière; Kim Bouillon; Cécile Billionnet; Philippe Ricordeau; François Alla; Mahmoud Zureik
Journal:  Circulation       Date:  2015-07-21       Impact factor: 29.690

9.  Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs.

Authors:  Joris Komen; Tomas Forslund; Paul Hjemdahl; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2017-06-29       Impact factor: 2.953

10.  Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.

Authors:  Géric Maura; Antoine Pariente; François Alla; Cécile Billionnet
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-28       Impact factor: 2.890

View more
  1 in total

1.  Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation.

Authors:  Alan Sugrue; David Sanborn; Mustapha Amin; Medhat Farwati; Haarini Sridhar; Azza Ahmed; Ramila Mehta; Konstantinos C Siontis; Siva K Mulpuru; Abhishek J Deshmukh; Bernard J Gersh; Samuel J Asirvatham; Malini Madhavan
Journal:  Am J Cardiol       Date:  2020-12-29       Impact factor: 2.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.